Unicycive Therapeutics, Inc. (UNCY)
Nasdaq · Healthcare · Biotechnology
$4.19−0.71%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $115M
- Forward P/E
- 2.5
- 52-week range
- $3.93 – $8.74
- 52-week change
- −8.86%
- EPS (trailing)
- −$1.72
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$26.6M
- Diluted EPS
- −$1.67
- Free cash flow
- −$31.3M
From the company’s annual report on SEC EDGAR.
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Headquarters: Mountain View, United States · 21 employees · unicycive.com